financetom
Business
financetom
/
Business
/
Columbia Sportswear Q2 Loss Narrows, Sales Rise; Sets Guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Columbia Sportswear Q2 Loss Narrows, Sales Rise; Sets Guidance
Jul 31, 2025 3:20 PM

06:07 PM EDT, 07/31/2025 (MT Newswires) -- Columbia Sportswear ( COLM ) reported Q2 loss late Thursday of $0.19 per diluted share, narrower than a loss of $0.20 a year earlier.

Net sales for the quarter that ended June 30 was $605.3 million, up from $570.2 million a year earlier.

Analysts surveyed by FactSet expected $588.5 billion.

For Q3, the firm expects EPS of $1.00 to $1.20 on revenue of $904 million to $922 million. Analysts expected revenue of $936.5 million.

For the full-year 2025, it expects net sales of $3.33 billion to $3.40 billion. Analysts expected $3.40 billion.

Shares of the company fell about 10% in after-hours activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Why Is Precision Oncology-Focused Aprea Therapeutics Stock Trading Higher On Monday?
Why Is Precision Oncology-Focused Aprea Therapeutics Stock Trading Higher On Monday?
Mar 11, 2024
Monday, Aprea Therapeutics Inc ( APRE ) announced that the FDA has cleared its Investigational New Drug (IND) application for APR-1051. “APR-1051 is a next-generation inhibitor of WEE1 kinase, and based on its unique characteristics, we believe it will be best in class,” said Oren Gilad, President and CEO of Aprea. “We look forward to evaluating therapeutic activity in patients, focusing on Cyclin...
US FDA approves Novo Nordisk's Wegovy for lowering heart risks
US FDA approves Novo Nordisk's Wegovy for lowering heart risks
Mar 11, 2024
(Reuters) -The U.S. Food and Drug Administration approved Novo Nordisk's weight-loss drug Wegovy on Friday for lowering the risk of stroke and heart attack in overweight or obese adults who do not have diabetes. Novo's widely used diabetes drug Ozempic and weight-loss drug Wegovy, both chemically known as semaglutide, belong to a class of drugs called GLP-1 agonists. Originally developed...
US Physical Therapy Reports Change in 2024 Medicare Rate Reduction
US Physical Therapy Reports Change in 2024 Medicare Rate Reduction
Mar 11, 2024
09:36 AM EDT, 03/11/2024 (MT Newswires) -- US Physical Therapy ( USPH ) said Monday that the 2024 Medicare rate reduction for therapy services will be roughly 1.8%, compared with 3.5% previously. The change was made in the Consolidated Appropriations Act, 2024, signed into law on March 8, the physical therapy clinics company added. The rate change will raise full-year...
WisdomTree Reports February Net Flows of $512 Million
WisdomTree Reports February Net Flows of $512 Million
Mar 11, 2024
09:37 AM EDT, 03/11/2024 (MT Newswires) -- WisdomTree ( WT ) reported February net flows Monday of $512 million, bringing total assets under management to about $102.86 billion. The company said its cryptocurrency product suite reached more than $100 million of annual net inflows, contrbuting to roughly $700 million in AUM at the month's end. Price: 8.5, Change: +0.08, Percent...
Copyright 2023-2026 - www.financetom.com All Rights Reserved